• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗生素已知化学类别流水线。

Pipeline of Known Chemical Classes of Antibiotics.

机构信息

Graduate Program in Technology of Chemical and Biochemical Processes, Technology Center, Federal University of Rio de Janeiro (UFRJ), EQ/UFRJ, Centro de Tecnologia, Bloco E, Ilha do Fundão, Rio de Janeiro-RJ 21949-900, Brazil.

Brazilian National Institute of Industrial Property, INPI/Rua Mayrink Veiga No. 9/19 andar, CEP 20090-910, Rio de Janeiro-RJ 20090-910, Brazil.

出版信息

Antibiotics (Basel). 2013 Dec 6;2(4):500-34. doi: 10.3390/antibiotics2040500.

DOI:10.3390/antibiotics2040500
PMID:27029317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4790266/
Abstract

Many approaches are used to discover new antibiotic compounds, one of the most widespread being the chemical modification of known antibiotics. This type of discovery has been so important in the development of new antibiotics that most antibiotics used today belong to the same chemical classes as antibiotics discovered in the 1950s and 1960s. Even though the discovery of new classes of antibiotics is urgently needed, the chemical modification of antibiotics in known classes is still widely used to discover new antibiotics, resulting in a great number of compounds in the discovery and clinical pipeline that belong to existing classes. In this scenario, the present article presents an overview of the R&D pipeline of new antibiotics in known classes of antibiotics, from discovery to clinical trial, in order to map out the technological trends in this type of antibiotic R&D, aiming to identify the chemical classes attracting most interest, their spectrum of activity, and the new subclasses under development. The result of the study shows that the new antibiotics in the pipeline belong to the following chemical classes: quinolones, aminoglycosides, macrolides, oxazolidinones, tetracyclines, pleuromutilins, beta-lactams, lipoglycopeptides, polymyxins and cyclic lipopeptides.

摘要

许多方法被用于发现新的抗生素化合物,其中最广泛的方法之一是对已知抗生素进行化学修饰。这种发现类型在新抗生素的开发中非常重要,以至于今天使用的大多数抗生素都属于与 20 世纪 50 年代和 60 年代发现的抗生素相同的化学类别。尽管迫切需要发现新的抗生素类别,但对已知类别中的抗生素进行化学修饰仍广泛用于发现新的抗生素,从而导致发现和临床管道中属于现有类别的化合物数量众多。在这种情况下,本文概述了已知类别抗生素中新抗生素的研发管道,从发现到临床试验,以绘制出这种抗生素研发的技术趋势,旨在确定最受关注的化学类别、它们的活性谱以及正在开发的新子类。研究结果表明,管道中的新抗生素属于以下化学类别:喹诺酮类、氨基糖苷类、大环内酯类、恶唑烷酮类、四环素类、截短侧耳素类、β-内酰胺类、糖肽类、多粘菌素类和环脂肽类。

相似文献

1
Pipeline of Known Chemical Classes of Antibiotics.抗生素已知化学类别流水线。
Antibiotics (Basel). 2013 Dec 6;2(4):500-34. doi: 10.3390/antibiotics2040500.
2
Antibiotic Discovery: Where Have We Come from, Where Do We Go?抗生素发现:我们来自何处,将去往何方?
Antibiotics (Basel). 2019 Apr 24;8(2):45. doi: 10.3390/antibiotics8020045.
3
Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.用于治疗社区获得性肺炎的处于I期和II期临床试验的研究性药物。
Expert Opin Investig Drugs. 2017 Nov;26(11):1239-1248. doi: 10.1080/13543784.2017.1385761. Epub 2017 Oct 3.
4
History of antimicrobial drug discovery: Major classes and health impact.抗菌药物发现的历史:主要类别和健康影响。
Biochem Pharmacol. 2017 Jun 1;133:4-19. doi: 10.1016/j.bcp.2016.10.001. Epub 2016 Oct 5.
5
Antibiotic discovery in the twenty-first century: current trends and future perspectives.二十一世纪的抗生素发现:当前趋势和未来展望。
J Antibiot (Tokyo). 2010 Aug;63(8):423-30. doi: 10.1038/ja.2010.62. Epub 2010 Jun 16.
6
Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?八肽抗生素能对抗广泛耐药(XDR)细菌吗?
Expert Rev Anti Infect Ther. 2018 Jun;16(6):485-499. doi: 10.1080/14787210.2018.1483240. Epub 2018 Jun 26.
7
[The search for novel antibiotics--strategies and current approaches].[新型抗生素的探索——策略与当前方法]
Berl Munch Tierarztl Wochenschr. 2014 Nov-Dec;127(11-12):498-512.
8
The antibiotic R&D pipeline: an update.抗生素研发管道:更新。
Curr Opin Microbiol. 2011 Oct;14(5):564-9. doi: 10.1016/j.mib.2011.08.002. Epub 2011 Aug 26.
9
[Looking for the new preparations for antibacterial therapy. I. New antibiotics and chemotherapeutics on the market].[寻找抗菌治疗的新制剂。I. 市场上的新型抗生素和化学治疗药物]
Przegl Epidemiol. 2012;66(4):567-73.
10
Physicochemical properties of antibiotics: A review with an emphasis on detection in the aquatic environment.抗生素的物理化学性质:综述,重点关注其在水环境中的检测。
Water Environ Res. 2020 Feb;92(2):177-188. doi: 10.1002/wer.1237. Epub 2019 Sep 24.

引用本文的文献

1
Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.抗菌肽:作用机制、应用及治疗潜力
Infect Drug Resist. 2025 Aug 27;18:4385-4426. doi: 10.2147/IDR.S514825. eCollection 2025.
2
Metabolic engineering approaches for the biosynthesis of antibiotics.用于抗生素生物合成的代谢工程方法。
Microb Cell Fact. 2025 Jan 31;24(1):35. doi: 10.1186/s12934-024-02628-2.
3
Treatment of MRSA Infection: Where are We?耐甲氧西林金黄色葡萄球菌感染的治疗:我们在哪里?
Curr Med Chem. 2024;31(28):4425-4460. doi: 10.2174/0109298673249381231130111352.
4
Pharmaceutical cocrystal of antibiotic drugs: A comprehensive review.抗生素药物的药用共晶体:全面综述。
Heliyon. 2022 Nov 30;8(12):e11872. doi: 10.1016/j.heliyon.2022.e11872. eCollection 2022 Dec.
5
Inhibitory Effects of β-Caryophyllene on Infection In Vitro and In Vivo.β-石竹烯对 感染的体外和体内抑制作用。
Int J Mol Sci. 2020 Feb 3;21(3):1008. doi: 10.3390/ijms21031008.
6
Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.耐多药革兰氏阳性微生物感染的新兴治疗选择
Microorganisms. 2020 Jan 30;8(2):191. doi: 10.3390/microorganisms8020191.
7
Antibiotic Discovery: Where Have We Come from, Where Do We Go?抗生素发现:我们来自何处,将去往何方?
Antibiotics (Basel). 2019 Apr 24;8(2):45. doi: 10.3390/antibiotics8020045.
8
Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.口服左旋左氧氟沙星后左氧氟沙星在肺部的药代动力学。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02297-17. Print 2018 Mar.
9
The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D.印度的药物研发与发展产业——二十年的小分子专利研发历程
ChemMedChem. 2017 Jun 7;12(11):786-818. doi: 10.1002/cmdc.201700043. Epub 2017 Jun 1.
10
β-Lactam Antibiotics Renaissance.β-内酰胺类抗生素的复兴。
Antibiotics (Basel). 2014 May 9;3(2):193-215. doi: 10.3390/antibiotics3020193.

本文引用的文献

1
In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.卡达唑胺对临床相关艰难梭菌分离株的体外活性以及在艰难梭菌感染的体外肠道模型中的活性。
J Antimicrob Chemother. 2014 Mar;69(3):697-705. doi: 10.1093/jac/dkt411. Epub 2013 Oct 14.
2
Investigational antimicrobial agents of 2013.2013 年的研究性抗菌药物。
Clin Microbiol Rev. 2013 Oct;26(4):792-821. doi: 10.1128/CMR.00033-13.
3
Antibiotics in the clinical pipeline in 2013.2013 年临床研发中的抗生素。
J Antibiot (Tokyo). 2013 Oct;66(10):571-91. doi: 10.1038/ja.2013.86. Epub 2013 Sep 4.
4
New antibiotics for bad bugs: where are we?新型抗生素应对耐药菌:进展如何?
Ann Clin Microbiol Antimicrob. 2013 Aug 28;12:22. doi: 10.1186/1476-0711-12-22.
5
The renaissance of polymyxins.多黏菌素的复兴。
Curr Med Chem. 2013;20(30):3759-73. doi: 10.2174/09298673113209990185.
6
In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.新型单硫霉素 BAL30072 单独及与美罗培南联用对多种重要革兰氏阴性病原体的体外活性。
Int J Antimicrob Agents. 2013 Oct;42(4):343-6. doi: 10.1016/j.ijantimicag.2013.05.010. Epub 2013 Jul 7.
7
Prospects for new antibiotics: a molecule-centered perspective.新型抗生素的前景:以分子为中心的视角。
J Antibiot (Tokyo). 2014 Jan;67(1):7-22. doi: 10.1038/ja.2013.49. Epub 2013 Jun 12.
8
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.MK-7655 联合亚胺培南对肠杆菌科和铜绿假单胞菌的活性。
J Antimicrob Chemother. 2013 Oct;68(10):2286-90. doi: 10.1093/jac/dkt178. Epub 2013 May 21.
9
Speculative strategies for new antibacterials: all roads should not lead to Rome.新型抗菌药物的投机策略:条条大路不应通向罗马。
J Antibiot (Tokyo). 2013 Jul;66(7):371-86. doi: 10.1038/ja.2013.27. Epub 2013 Apr 24.
10
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.10 x '20 进展——开发针对革兰氏阴性杆菌的新型药物:来自美国传染病学会的最新进展。
Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17.